Science Immunology Review Time

AAAS gives a clear picture of editorial level and journal identity, and its journal metrics page publishes full-year 2025 turnaround medians for Science Immunology research content.

The public materials tell you:

• Science Immunology is a Science-family journal for critical advances across immunology

• the journal is broad across systems, including human work

• the journal is selective and monthly

• the journal is built for high-consequence immunology rather than ordinary specialty throughput

The AAAS journal metrics page adds, for full year 2025 and research content (it excludes Reviews):

• a median of 5 days from submission to first decision, meaning the decision to send the paper to review or to reject it

• a median of 64 days from submission to the first post-review decision, and 210 days from submission to acceptance

• a median of 25 days from acceptance to online publication

• 2,087 submissions, of which 12.3% were externally reviewed, and a 5.2% accept rate among manuscripts with a final decision

They do not tell you:

• a timeline for your own manuscript

• what each portal status means for your paper

That means the safest author model comes from pairing the official AAAS medians with the SciRev community timing layer.

That is the real planning model. If the manuscript is not obviously a Science Immunology paper, the fast part of the process is usually the rejection.

The journal often feels fast because the editorial screen is not pretending to be democratic. It is making a high-bar first read.

Editors are usually deciding quickly:

• is this a broad immunology advance

• is the main consequence visible without niche context

• is the mechanism strong enough for the claim

• does this really belong in a Science-family immunology lane

If the answer is no, authors often learn that quickly.

The slower cases are the manuscripts good enough to survive the first read.

That longer path usually reflects:

• reviewer demand for stronger mechanistic closure

• papers that are strong but not obviously broad enough on first framing

• work that needs a cleaner field-level consequence argument

• revision cycles where the immunology advance is real but the editorial level still has to be earned

So the timing problem is often not reviewer laziness. It is editorial level.

That profile fits the timing pattern. A journal with this editorial position does not need to review every good paper fully, so the fastest path through it is often the rejection.

The selectivity is the point. Editors can afford to filter hard at the desk because their job is to protect a flagship lane, not to find a home for every technically sound immunology study.

This comparison matters because many timing disappointments are really owner-journal mistakes.

For year-over-year citation metrics data, see the science immunology citation metrics page.

Directionally, the open citation signal is down from 14.04 in 2023 to 13.14 in 2024. That does not mean the journal became soft or slow. It means the post-peak immunology citation environment normalized while the journal stayed elite. Authors should read the timing model through editorial selectivity, not through nostalgia for a hotter citation cycle.

Review-time data hides the most important distinction at this journal:

• a fast desk rejection is often a fit verdict, not an administrative one

• a several-month accepted path often means the journal took the paper seriously

• the real variable is not only speed, but whether the paper is operating at flagship broad-immunology level

That is why timing numbers matter, but the hidden variable is still editorial level.

Across Science Immunology manuscripts, the biggest timing mistake is treating the journal like a general reward for strong immunology.

It is not.

The papers that move best here usually have:

• a broad immunology consequence visible on page one

• mechanism strong enough to justify the headline

• relevance that travels beyond one receptor, pathway, or disease niche

• a first read that does not require insider context to feel important

Those traits improve timing because they reduce the chance that the paper dies at desk or stalls in a revision fight over its real level.

For Science Immunology-targeted manuscripts, three patterns most consistently predict slow review at Science Immunology (AAAS). Of manuscripts we screened in 2025 targeting Science Immunology and peer venues, the patterns below are the same ones our reviewers flag in real time. The named editorial-culture quirk: Science Immunology professional editors emphasize cross-disciplinary readability with mechanistic depth; subfield-bounded papers extend revision rounds.

Scope-fit ambiguity in the abstract. Science Immunology editors move fastest on manuscripts whose contribution is obviously aligned with the journal's editorial scope (immunology from basic to clinical research). The named failure pattern: subfield-bounded immunology papers without cross-disciplinary framing extend revision rounds. Check whether your abstract reads to Science Immunology's scope →

Methods package incomplete for the journal's reviewer pool. Science Immunology reviewers expect specific methodological detail. Preliminary mechanistic claims without translational implications extend reviewer consultation. Check if your methods package is reviewer-complete →

Reference-list and clean-citation failure mode. Editorial team at Science Immunology (AAAS) screens reference lists for retracted-paper inclusion. Check whether your reference list is clean against Crossref + Retraction Watch →

Editorial detail (for desk-screen calibration). Verify the current Editor-in-Chief and handling-editor list on the journal's editorial-team page before quoting any name in a submission cover letter. Submission portal: AAAS journal page. Manuscript constraints: an abstract of 125 words or fewer is preferred with a 250-word maximum at submission, and Research Articles should be 6,000 to 8,000 words with 5 to 8 figures (the journal's information-for-authors page sets a ceiling of 8,000 words and up to 8 figures or tables).

We reviewed each of these constraints against current journal author guidelines (accessed 2026-10-09); evidence basis for the patterns above includes both publicly documented author-guidelines and our internal anonymized submission corpus.

Manusights submission-corpus signal for Science Immunology (AAAS). Of the manuscripts our team screened before submission to Science Immunology and peer venues in 2025, the editorial-culture mismatch most consistent across the cohort is Science Immunology professional editors emphasize cross-disciplinary readability with mechanistic depth; subfield-bounded papers extend revision rounds.

In our analysis of anonymized Science Immunology-targeted submissions, the documented review timeline shows a bimodal distribution between manuscripts that clear Science Immunology's scope-fit threshold within the first week and those that get extended editorial-board consultation. Top-line triage is handled by the journal's editorial team; verify the current handling editor on the journal's editorial-team page before quoting any name in a cover letter.

For Science Immunology, speed matters less than broad immunology consequence and mechanistic closure.

That is why the better next reads are:

• Science Immunology submission guide

• Science Immunology citation metrics

• How to avoid desk rejection at Science Immunology

• How to choose the right journal for your paper

A Science Immunology fit check is usually more useful than anchoring on the five-day desk number alone.

Science Immunology review time is fast only at the first gate. The journal can reject quickly, but the papers that survive that gate usually enter a real several-month review process. Authors should plan around two clocks: rapid editorial triage and a multi-month path for manuscripts that genuinely look like broad immunology advances.

The Manusights Science Immunology readiness scan. This guide tells you what Science Immunology (AAAS)'s editors look for in the first 1-2 weeks of triage. The review tells you whether your paper passes that check before you submit. We have reviewed manuscripts targeting Science Immunology (AAAS) and peer venues; the named patterns below are the same ones the journal's handling editors and outside reviewers flag at the desk-screen and first-review stages.

AAAS 2025 medians: 5 days to first decision and 64 days to the first post-review decision; authors of papers not selected for in-depth review are notified within about a week. 60-day money-back guarantee. Your manuscript is not used for model training, and access is limited to the review workflow.